Clinical Trials
The following clinical trials are currently recruiting participants. If you would like more information regarding the trial or how to participate, please contact the study coordinator or complete the Nephrology Clinical Research Interest Form and we will contact you.
| Trial Name | Sponsor | Summary | Details | Study Coordinator |
|---|---|---|---|---|
| EPOC PKD | NIH | Observational study collecting blood and urine and clinical information from individuals in the early stages PKD. The long-term goal is to develop new knowledge of biomarkers that indicate changes in the disease progression. |
|
|
| PKD Repository | KUMC Jared Grantham Kidney Institute | The KI has a biorepository of blood and urine samples from adults with Polycystic Kidney Disease (PKD) in order to provide specimens to investigators for the discovery of biomarkers. |
|
|
| VX24-KDO-901 | Vertex Pharmaceuticals Incorporated |
A 2-part study to determine the prevalence and clinical characteristics associated with PKD1 Gene Variant Groups in ADPKD. Part A is the genotyping visit and Part B is a follow-up period to evaluate the changes in ADPKD related characteristics. |
|
| Trial Name | Sponsor | Summary | Details | Study Coordinator |
|---|---|---|---|---|
| SIRIUS | Novartis | A Phase 3 trial to see the efficacy, safety, and tolerability of ianalumab on top of standard of care therapy in participants with active Lupus Nephritis. |
|
| Trial Name | Sponsor | Summary | Details | Study Coordinator |
|---|---|---|---|---|
| EASI-KIDNEY | Boeringer Ingelheim | Studies of heart and kidney protection with BI690517 in combination with Empagliflozin in patients with Chronic Kidney Disease. |
|
|
| Amplitude VX21-147-301 | Vertex Pharmaceuticals Incorporated | A phase 2/3 study for individuals of African ancestry with APOL1-Mediated Nondiabetic Chronic Kidney Disease and an increased level of protein in their urine. VX-147 is being studied to determine if it can slow or stop the worsening of kidney function. |
|
|
| Fabry Registry | Genzyme | Collection of clinical data of patients with Fabry Disease to better understand Fabry Disease and its management. |
|
|
| Neptune | National Institutes of Health, NIDDK, Nephcure Kidney International, University of Michigan | To learn more about 4 diseases which cause Nephrotic Syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN) and Alport Syndrome. Collects health information and lab samples from patients. |
|
|
| TRIUMPH-OUTCOMES | Eli Lilly | Phase 3: Effect of retatrutide on the reduction of MACE and/or kidney outcomes in participants with BMI ≥27 kg/m2 and ASCVD and/or CKD. Retatrutide is a triple agonist of receptors for GLP-1 (glucacon-like peptide-1) to suppress appetite, enhance post-prandial insulin; GIP (glucose insulintropic peptide) to regulate lipid metabolism, enhance post-prandial insulin, and the glucagon receptor. |
Inclusion Details
CKD includes: Stage 3b or less with eGFR <45 mL/min/1.73 m2 and UACR >30 mg/g or eGFR <60 mL/min/1.73 m2 and UACR >100 mg/g, or or eGFR <75 mL/min/1.73 m2 and UACR >300 mg/g. but NOT eGFR < 20 and NOT urine ACR > 5000 mcg/mg ASCVD includes cad, stroke, carotid disease, or PAD by ABI or imaging |
| Trial Name | Sponsor | Summary | Inclusion Details | Study Coordinator |
|---|---|---|---|---|
| RHYTHM BP | PCORI |
Remote Hypertension Tracking, Help and Management to improve Blood Pressure |
|
General Nephrology Coordinators
Cathy Creed, RN
ccreed@kumc.edu
(913) 588-0053
Jordan Haferbier - Clinical research Coordinator
jhaferbier@kumc.edu
(913) 588-8983
Jordan Elliott
jelliott112@kumc.edu
(913) 588-7691
Nephrology Transplant Coordinators
Jessica Reed
jreed19@kumc.edu
(913) 574-0894
Sean O'Brien
sobrien5@kumc.edu
(913) 574-0895
Clinical Research Assistants
Abigayle Joyce
ajoyce3@kumc.edu
(913) 574-3255
Emma Stevens
estevens4@kumc.edu